Oncology exploration: Charting cancer medicinal chemistry space

Drug Discovery Today

Volumn 11, Issue 3-4, 2006, Pages 149-159

  Lloyd, David G ^a   Golfis, Georgia ^a   Knox, Andrew J S ^a   Fayne, Darren ^a   Meegan, Mary J ^a   Oprea, Tudor I ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANASTROZOLE; ANTIANDROGEN; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BLEOMYCIN A2; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; INTERCALATING AGENT; MERCAPTOPURINE; METHOTREXATE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TETRAPLATIN; TRASTUZUMAB; UNINDEXED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROINTESTINAL TUMOR; GENOTOXICITY; HODGKIN DISEASE; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MATHEMATICAL COMPUTING; MOLECULAR INTERACTION; MYELOMA; OSTEOPOROSIS; OVARY CANCER; PRINCIPAL COMPONENT ANALYSIS; PROSTATE CANCER; REVIEW; TESTIS CANCER; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; PRINCIPAL COMPONENT ANALYSIS;

EID: 33644861259     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03688-3     Document Type: Review

References (50)

1. Desany B., Zhang Z. Bioinformatics and cancer target discovery Drug Discov. Today 9 2004 795 802
2. Wong C.F. Exploiting novel cell cycle targets in the development of anticancer agents Curr. Cancer Drug Targets 5 2005 85 102
3. Cozzi P. Recent anticancer cytotoxic agents Curr. Med. Chem. Anti-Canc. Agents 4 2004 93 121
4. Martinez R., Chacon-Garcia L. The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work Curr. Med. Chem. 12 2005 127 151
5. Piazza F., Semenzato G. Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction Expert Rev. Anticancer Ther. 4 2004 387 400
6. Benvenuti S. Identification of cancer genes by mutational profiling of tumor genomes FEBS Lett. 579 2005 1884 1890
7. Chen E.X., Siu L.L. Development of molecular targeted anticancer agents: successes, failures and future directions Curr. Pharm. Des. 11 2005 265 272
8. McGuire J.J. Anticancer antifolates: current status and future directions Curr. Pharm. Des. 9 2003 2593 2613
9. Brathe A. Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines Bioorg. Med. Chem. Lett. 13 2003 877 880
10. Malet-Martino M. The prodrugs of 5-fluorouracil Curr. Med. Chem. Anti-Canc. Agents 2 2002 267 310
11. Izbicka E., Tolcher A.W. Development of novel alkylating drugs as anticancer agents Curr. Opin. Investig. Drugs 5 2004 587 591
12. Brana M.F. Intercalators as anticancer drugs Curr. Pharm. Des. 7 2001 1745 1780
13. Larsen A.K. Catalytic topoisomerase II inhibitors in cancer therapy Pharmacol. Ther. 99 2003 167 181
14. Saglio G. Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia Ann. N. Y. Acad. Sci. 1028 2004 423 431
15. Collier L.S. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse Nature 436 2005 272 276
16. Vieth M. Kinomics: characterizing the therapeutically validated kinase space Drug Discov. Today 10 2005 839 846
17. Druker B.J. Imatinib as a paradigm of targeted therapies Adv. Cancer Res. 91 2004 1 30
18. Mitsiades C.S. Proteasome inhibition as a therapeutic strategy for hematologic malignancies Expert Rev. Anticancer Ther. 5 2005 465 476
19. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem. Anti-Canc. Agents 2 2002 1 17
20. Meegan M.J., Lloyd D.G. Advances in the science of estrogen receptor modulation Curr. Med. Chem. 10 2003 181 210
21. Lloyd D.G. Benzoxepin-derived estrogen receptor modulators: a novel molecular scaffold for the estrogen receptor J. Med. Chem. 47 2004 5612 5615
22. Revankar C.M. A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 2005 1625 1630
23. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer Urology 60 Suppl. 1 2002 132 138
24. Gaillard-Moguilewsky M. Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy Urology 37 Suppl. 2 1991 5 12
25. Narashimamurthy J. Aromatase inhibitors: a new paradigm in breast cancer treatment Curr. Med. Chem. Anti-Canc. Agents 4 2004 523 534
26. Ingle J.N., Suman V.J. Aromatase inhibitors for therapy of advanced breast cancer J. Steroid Biochem. Mol. Biol. 95 2005 113 119
27. Wang J., Ramnarayan K. Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds J. Comb. Chem. 1 1999 524 533
28. Jackson J.E. A Users Guide to Principal Components 1991 Wiley
29. Mestres J. Virtual screening: a real screening complement to high-throughput screening Biochem. Soc. Trans. 30 2002 797 799
30. Hou T., Xu X. Recent development and application of virtual screening in drug discovery: an overview Curr. Pharm. Des. 10 2004 1011 1033
31. Lipinski C.A. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
32. Congreve M. A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
33. Fattori D. Molecular recognition: The fragment approach in lead generation Drug Discov. Today 9 2004 229 238
34. Leach A.R., Hann M.M. The in silico world of virtual libraries Drug Discov. Today 5 2000 326 336
35. Shuttleworth S.J. Design and synthesis of protein superfamily-targeted chemical libraries for lead identification and optimization Curr. Med. Chem. 12 2005 1239 1281
36. Olah M.M. Strategies for compound selection Curr. Drug Disc. Tech. 1 2004 211 220
37. Chen G. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score J. Comb. Chem. 7 2005 398 406
38. Oprea T.I. Lead structure searching: are we looking at the appropriate property? J. Comput. Aided Mol. Des. 16 2002 325 334
39. Lyne P.D. Structure-based virtual screening: an overview Drug Discov. Today 7 2002 1047 1055
40. Oprea T.I. Property distribution of drug-related chemical databases J. Comput. Aided Mol. Des. 14 2000 251 264
41. Harper G. Design of a compound screening collection for use in high-throughput screening Comb. Chem. High Throughput Screen 7 2004 63 70
42. Hann M.M., Oprea T.I. Pursuing the leadlikeness concept in pharmaceutical research Curr. Opin. Chem. Biol. 8 2004 255 263
43. Walters W.P., Murcko M.A. Prediction of "drug-likeness" Adv. Drug Deliv. Rev. 54 2002 255 271
44. Lipinski C.A. Drug-like properties and the cause of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249
45. Wang R. A new atom-additive method for calculating partition coefficients J. Chem. Inf. Comput. Sci. 37 1997 615 621
46. Adams D. The hitch-hiker's guide to the galaxy 1979 Pan Books
47. Oprea T.I., Gottfries J. Chemography: the art of navigating in chemical space J. Comb. Chem. 3 2001 157 166
48. Olah M. WOMBAT: world of molecular bioactivity Oprea T.I. Chemoinformatics in drug discovery 2004 Wiley-VCH 223 239
49. Irwin J.J., Shoichet B.K. ZINC - a free database of commercially available compounds for virtual screening J. Chem. Inf. Model. 45 2005 177 182
50. Haggarty S.J. Mapping chemical space using molecular descriptors and chemical genetics: deacetylase inhibitors Comb. Chem. High Throughput Screen 7 2004 669 676